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four clusters (cluster 1  UK, Denmark, Norway, Nether-
lands; cluster 2  Germany, Finland; cluster 3  Belgium;
cluster 4  France). In the multilevel model, variances were
observed operating at the different levels which could be ex-
plained in terms of the general characteristics of the sites.
CONCLUSIONS: The results of this analysis suggest that
cluster analysis and multilevel modeling techniques can
be valuable tools in the exploration of multinational eco-
nomic data, although they require considerable care in
practice. The presence of clustering may have important
implications for costing and the pooling of multinational
economic evaluation data.
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OBJECTIVES: The purpose of this study was to evaluate
the impact of price change on the willingness to pay
(WTP) of patients with urinary incontinence.
METHODS: A sample of 41 women with urinary incon-
tinence (UI) from Seattle and Philadelphia were inter-
viewed. The questionnaire contained a WTP question
with 11 bids ranging from $1 to $200. Two versions of
the questionnaire were administered, one for “improve-
ment” and one for “cure.” Respondents recorded whether
they would accept or reject each bid (“price”) at the
stated dollar value. The analysis was conducted using the
modified price elasticity concept defined by the percent
change in the number of people who were willing to pay
divided by the percent change in price.
RESULTS: Elasticity comparison between improvement
and cure showed that, in general, people’s WTP was
more “elastic” for improvement than it was for cure. In
the lower price range (from $10 to $50), the WTP for both
improvement and cure were inelastic (elasticity less than
one). For the higher price range ($50 to $200), only WTP
for improvement showed elasticity greater than one.
CONCLUSIONS: Regardless the price range, people are
more sensitive to the price change for a scenario promising
“improvement” than they are for “cure.” Therefore,
changes in price affect patients’ WTP for improvement
more than it will for cure. For a price range up to $50,
people will react similarly to price changes for both “im-
provement” and “cure.” People will react differently,
however (more elastic to improvement) at a price range
greater than $50. Therefore, the issue of the treatment out-
come (improvement versus cure) has a notable impact on
patient WTP when costs to them exceed $50.
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With the ongoing discussion about whether both costs
and outcomes should be discounted, alternate model con-
struction reflecting these options can be very informative.
Furthermore, the area of osteoporosis would dictate that
age adjusted fracture rates would be a particularly influ-
ential component to consider in model construction.
OBJECTIVE: This analysis reports the impact of step-
wise inclusion of the discounting costs and outcomes and
an age-adjustment on increment cost-effectiveness ratios.
METHODS: The two alternatives included hormone re-
placement therapy with calcium supplementation com-
pared with calcium supplementation alone in a cohort of
women age 50 to 90 years. The effectiveness measure
was fractures avoided.
RESULTS: The base model discounts only costs with no
age-adjustment for fracture rates (incremental CER:
$56,178.16, favoring hormone therapy). The model dis-
counting both costs and outcomes with no age-adjustment
for fracture rates, resulted in an incremental CER of
$37,817.38 per fracture avoided. Age-adjustment of frac-
ture rates resulted in incremental CER of $83,561.59 per
fracture avoided (discounted costs only) and $42,232.68
per fracture avoided (discounted costs and outcomes). All
models favored hormone replacement therapy and did
not result in any decision changes. At the end of 40 years,
Markov analysis demonstrated that age-adjustment of
fracture rates induced a shift to more desirable states. The
most dramatic shift was 14.87 and 5.15 more women out
of 1000 alive with no fracture in the hormone and calcium
arms, respectively.
CONCLUSION: The effect of discounting did not
change the decision outcome of the osteoporosis Markov
model. However, the magnitude of the change in Markov
state composition was dramatic as a result of the age ad-
justment to fracture rates.
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Tailoring the results from clinical trials and associated
pharmacoeconomic analyses to specific populations is
frequently requested by managed care companies. Mod-
els based on clinical trials and analyses often use pub-
lished results that typically present only study means (or
means and variances). However, underlying distributions
of results are not always normally or uniformly distrib-
uted, leading to potentially biased model predictions.
